Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Ascensia Diabetes Care Denmark ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Bankruptcy risk for industry   2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7%   Bankruptcy risk   0.6% 0.5% 0.4% 0.4% 0.5% 0.5% 4.3% 4.1%   Credit score (0-100)   98 99 100 100 99 99 48 49   Credit rating   AA AAA AAA AAA AAA AAA BBB BBB   Credit limit (kDKK)   1,949.3 2,118.8 2,550.2 3,082.8 1,700.1 1,738.4 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   12,071 12,171 12,780 15,639 15,236 11,510 0.0 0.0   EBITDA   5,639 5,243 5,743 5,885 3,431 3,584 0.0 0.0   EBIT   4,267 2,913 3,448 3,621 1,336 1,905 0.0 0.0   Pre-tax profit (PTP)   3,926.4 2,817.3 3,329.0 3,487.5 1,270.5 1,827.8 0.0 0.0   Net earnings   3,059.5 2,137.6 2,568.9 2,681.1 989.6 1,423.8 0.0 0.0   Pre-tax profit without non-rec. items   3,926 2,817 3,329 3,487 1,271 1,828 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Tangible assets total   0.0 1,808 1,525 982 739 883 0.0 0.0   Shareholders equity total   11,954 14,091 16,660 19,341 11,831 10,255 8,805 8,805   Interest-bearing liabilities   13,459 10,832 7,447 4,222 2,482 6,701 0.0 0.0   Balance sheet total (assets)   34,329 32,841 31,115 29,871 21,625 25,554 8,805 8,805   Net Debt   5,970 3,675 -2,177 -9,358 -663 -1,428 -2,296 -2,296     See the entire balance sheet 1000.0 Volume  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   12,071 12,171 12,780 15,639 15,236 11,510 0.0 0.0   Gross profit growth   31.9% 0.8% 5.0% 22.4% -2.6% -24.5% -100.0% 0.0%   Employees   8 9 8 7 10 8 0 0   Employee growth %   0.0% 12.5% -11.1% -12.5% 42.9% -20.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   34,329 32,841 31,115 29,871 21,625 25,554 8,805 8,805   Balance sheet change%   -0.8% -4.3% -5.3% -4.0% -27.6% 18.2% -65.5% 0.0%   Added value   5,638.8 5,242.7 5,743.1 5,885.1 3,599.6 3,584.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -2,744 -1,894 -3,949 -4,179 -3,577 -2,375 -883 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   35.3% 23.9% 27.0% 23.2% 8.8% 16.5% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   12.4% 8.7% 10.8% 11.9% 5.2% 8.1% 0.0% 0.0%   ROI %   15.6% 10.8% 12.8% 13.8% 6.3% 10.9% 0.0% 0.0%   ROE %   29.4% 16.4% 16.7% 14.9% 6.3% 12.9% 0.0% 0.0%   1000.0 Solidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Equity ratio %   34.8% 42.9% 53.5% 64.8% 54.7% 40.1% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   105.9% 70.1% -37.9% -159.0% -19.3% -39.8% 0.0% 0.0%   Gearing %   112.6% 76.9% 44.7% 21.8% 21.0% 65.3% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.1% 0.8% 1.3% 2.3% 1.9% 1.7% 0.0% 0.0%   1000.0 Liquidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Quick Ratio   1.0 1.2 1.6 2.5 1.7 1.3 0.0 0.0   Current Ratio   1.0 1.2 1.6 2.5 1.7 1.3 0.0 0.0   Cash and cash equivalent   7,489.3 7,157.5 9,624.4 13,579.8 3,145.2 8,128.2 0.0 0.0   1000.0 Capital use efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   600.0 3,443.8 7,526.1 11,974.1 5,406.3 4,427.3 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   705 583 718 841 360 448 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   705 583 718 841 343 448 0 0   EBIT / employee   533 324 431 517 134 238 0 0   Net earnings / employee   382 238 321 383 99 178 0 0